Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Raised to Strong-Buy at Zacks Research

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) was upgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a report released on Wednesday,Zacks.com reports.

A number of other analysts have also weighed in on the stock. Jefferies Financial Group upped their price target on shares of Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the stock a “buy” rating in a research note on Tuesday, April 28th. Wells Fargo & Company raised their price objective on shares of Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the company an “overweight” rating in a research note on Wednesday, April 29th. Wedbush boosted their target price on Kiniksa Pharmaceuticals International from $58.00 to $59.00 and gave the stock an “outperform” rating in a report on Wednesday, April 29th. Citigroup upped their target price on Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. Finally, Canaccord Genuity Group increased their price target on Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the company a “buy” rating in a research note on Wednesday, April 29th. One investment analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $60.86.

Kiniksa Pharmaceuticals International Stock Performance

NASDAQ:KNSA opened at $55.11 on Wednesday. The stock has a market cap of $4.24 billion, a price-to-earnings ratio of 61.23 and a beta of 0.12. Kiniksa Pharmaceuticals International has a 1 year low of $26.27 and a 1 year high of $59.87. The business has a fifty day moving average of $50.86 and a 200-day moving average of $46.27.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, April 28th. The company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.09. The business had revenue of $214.27 million during the quarter, compared to the consensus estimate of $206.11 million. Kiniksa Pharmaceuticals International had a net margin of 9.69% and a return on equity of 13.26%. The company’s quarterly revenue was up 55.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.11 earnings per share. On average, equities research analysts predict that Kiniksa Pharmaceuticals International will post 1.24 EPS for the current year.

Insider Buying and Selling

In other news, insider John F. Paolini sold 58,424 shares of the firm’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $53.71, for a total transaction of $3,137,953.04. Following the completion of the transaction, the insider owned 65,623 shares in the company, valued at approximately $3,524,611.33. This trade represents a 47.10% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Sanj K. Patel sold 48,565 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $54.02, for a total transaction of $2,623,481.30. Following the completion of the transaction, the chief executive officer directly owned 48,565 shares in the company, valued at $2,623,481.30. This represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 653,301 shares of company stock worth $34,046,073 in the last ninety days. Insiders own 51.98% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in KNSA. KBC Group NV bought a new position in shares of Kiniksa Pharmaceuticals International in the first quarter valued at $34,000. Smartleaf Asset Management LLC acquired a new position in shares of Kiniksa Pharmaceuticals International in the 4th quarter worth $36,000. EverSource Wealth Advisors LLC grew its holdings in shares of Kiniksa Pharmaceuticals International by 140.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after acquiring an additional 532 shares during the last quarter. Nano Cap New Millennium Growth Fund L P acquired a new position in shares of Kiniksa Pharmaceuticals International in the 4th quarter worth $41,000. Finally, CIBC Private Wealth Group LLC acquired a new stake in shares of Kiniksa Pharmaceuticals International during the fourth quarter worth $41,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1? blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.